Xinqikang Pharmaceutical

Xinqikang Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses primarily on endocrine-related diseases and oncology, with a particular emphasis on targeting nuclear receptors such as the estrogen and androgen receptors. Its lead programs are designed to address unmet medical needs in hormone-sensitive cancers, including advanced breast and prostate cancers. Xinqikang leverages its internal R&D capabilities to advance a pipeline of candidates through early-stage clinical trials in the Chinese market.